O‐GlcNAc regulates anti‐fibrotic genes in lung fibroblasts through EZH2

Abstract

AbstractEpigenetic modifications are involved in fibrotic diseases, such as idiopathic pulmonary fibrosis (IPF), and contribute to the silencing of anti‐fibrotic genes. H3K27me3, a key repressive histone mark, is catalysed by the methyltransferase enhancer of Zeste homologue 2 (EZH2), which is regulated by the post‐translational modification, O‐linked N‐Acetylglucosamine (O‐GlcNAc). In this study, we explored the effects of O‐GlcNAc and EZH2 on the expression of antifibrotic genes, cyclooxygenase‐2 (Cox2) and Heme Oxygenase (Homx1). The expression of Cox2 and Hmox1 was examined in primary IPF or non‐IPF lung fibroblasts with or without EZH2 inhibitor EZP6438, O‐GlcNAc transferase (OGT) inhibitor (OSMI‐1) or O‐GlcNAcase (OGA) inhibitor (thiamet G). Non‐IPF cells were also subjected to TGF‐β1 with or without OGT inhibition. The reduced expression of Cox2 and Hmox1 in IPF lung fibroblasts is restored by OGT inhibition. In non‐IPF fibroblasts, TGF‐β1 treatment reduces Cox2 and Hmox1 expression, which was restored by OGT inhibition. ChIP assays demonstrated that the association of H3K27me3 is reduced at the Cox2 and Hmox1 promoter regions following OGT or EZH2 inhibition. EZH2 levels and stability were decreased by reducing O‐GlcNAc. Our study provided a novel mechanism of O‐GlcNAc modification in regulating anti‐fibrotic genes in lung fibroblasts and in the pathogenesis of IPF.